参考文献/References:
[1] Matheus AS,Tannus LR,Cobas RA,et al. Impact of diabetes on cardiovascular disease:an update[J]. Int J Hypertens,2013,2013:653789.
[2] Vesa CM,Popa L,Popa AR,et al. Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors[J]. Diagnostics (Basel),2020,10(5):314.
[3] Alghatrif M,Kuo YF,Al Snih S,et al. Trends in hypertension prevalence,awareness,treatment and control in older Mexican Americans,1993-2005[J]. Ann Epidemiol,2011,21(1):15-25.
[4] Haffner SM,Lehto S,R?nnemaa T,et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction[J]. N Engl J Med,1998,339(4):229-234.
[5] Busch RS,Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy:a complementary approach to the treatment of type 2 diabetes[J]. Postgrad Med,2017,129(7):686-697.
[6] Marso SP,Daniels GH,Brown-Frandsen K,et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2016,375(4):311-322.
[7] Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial[J]. Circulation,2010,122(8):844-846.
[8] Verma S,Mcmurray JJV,Cherney DZI. the metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition:the search for the sweet spot in heart failure[J]. JAMA Cardiol,2017,2(9):939-940.
[9] Sattar N,Mclaren J,Kristensen SL,et al. SGLT2 Inhibition and cardiovascular events:why did EMPA-REG Outcomes surprise and what were the likely mechanisms?[J]. Diabetologia,2016,59(7):1333-1339.
[10] Kario K,Okada K,Kato M,et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension:results from the randomized,placebo-controlled SACRA study[J]. Circulation,2018,139(18):2089-2097.
[11] Mcmurray JJV,Solomon SD,Inzucchi SE,et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2019,381(21):1995-2008.
[12] Patorno E,Pawar A,Franklin JM,et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care[J]. Circulation,2019,139(25):2822-2830.
[13] Ferrannini E,Mark M,Mayoux E. CV protection in the EMPA-REG OUTCOME trial:a "thrifty substrate" hypothesis[J]. Diabetes Care,2016,39(7):1108-1114.
[14] Kappel BA,Lehrke M,Schutt K,et al. Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease[J]. Circulation,2017,136(10):969-972.
[15] Kang S,Verma S,Hassanabad AF,et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts:novel translational clues to explain EMPA-REG OUTCOME results[J]. Can J Cardiol,2020,36(4):543-553.
[16] Trujillo JM,Nuffer W,Smith BA. GLP-1 receptor agonists:an updated review of head-to-head clinical studies[J]. Ther Adv Endocrinol Metab,2021,12:2042018821997320.
[17] Marre M,Shaw J,Br?ndle M,et al. Liraglutide,a once-daily human GLP-1 analogue,added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)[J]. Diabet Med,2009,26(3):268-278.
[18] Rakipovski G,Rolin B,N?hr J,et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in?ApoE(-/-) and LDLr(-/-) mice by?a?mechanism that includes inflammatory pathways[J]. JACC Basic Transl Sci,2018,3(6):844-857.
[19] Sattar N,Lee MMY,Kristensen SL,et al. Cardiovascular,mortality,and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes:a systematic review and meta-analysis of randomised trials[J]. Lancet Diabetes Endocrinol,2021,9(10):653-662.
[20] Verma S,Mcmurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit:a state-of-the-art review[J]. Diabetologia,2018,61(10):2108-2117.
[21] Gerstein HC,Sattar N,Rosenstock J,et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes[J]. N Engl J Med,2021,385(10):896-907.
[22] Frías JP,Guja C,Hardy E,et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8):a 28 week,multicentre,double-blind,phase 3,randomised controlled trial[J]. Lancet Diabetes Endocrinol,2016,4(12):1004-1016.
[23] Ludvik B,Frías JP,Tinahones FJ,et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10):a 24-week,randomised,double-blind,placebo-controlled trial[J]. Lancet Diabetes Endocrinol,2018,6(5):370-381.
[24] Zinman B,Bhosekar V,Busch R,et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9):a randomised,placebo-controlled trial[J]. Lancet Diabetes Endocrinol,2019,7(5):356-367.
[25] Carretero Gómez J,Arévalo Lorido JC,Gómez Huelgas R,et al. Combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes:a real-world evidence study[J]. Can J Diabetes,2019,43(3):186-192.
[26] Iacobellis G,Singh N,Wharton S,et al. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects[J]. Obesity (Silver Spring),2008,16(7):1693-1697.
[27] Mahabadi AA,Berg MH,Lehmann N,et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population:the Heinz Nixdorf Recall Study[J]. J Am Coll Cardiol,2013,61(13):1388-1395.
[28] Iacobellis G,Mohseni M,Bianco SD,et al. Liraglutide causes large and rapid epicardial fat reduction[J]. Obesity (Silver Spring),2017,25(2):311-316.
[29] Yagi S,Hirata Y,Ise T,et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus[J]. Diabetol Metab Syndr,2017,9:78.
[30] 王彪,吴燕,周芩,等.达格列净联合利拉鲁肽对2型糖尿病伴肥胖患者胰岛素抵抗及血清炎性因子水平的影响[J].中国药业,2021,30(13):47-50.
[31] 温彩霞,杨晓燕,卫娟,等. 利拉鲁肽联合达格列净对超重或肥胖2型糖尿病患者肾功能、氧化应激以及内脏脂肪含量的影响[J]. 现代生物医学进展,2021,21(12):2271-2272.
[32] Kuhadiya ND,Mahmood I. Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria:A case series[J]. Clin Case Rep,2021,9(4):2310-2316.
相似文献/References:
[1]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[2]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[3]马赛 左庆娟 张国瑞 郭艺芳.钠氢交换体可能是钠-葡萄糖共转运蛋白-2抑制剂心力衰竭获益及不良反应的潜在靶点[J].心血管病学进展,2021,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.004]
MA Sai,ZUO Qingjuan,ZHANG Guorui,et al.Na+/H+?Exchanger:The?Potential?Target?for?the?Benefits?and?Adverse?Effects?of?Sodium-glucose?Co-Transporter?2?Inhibitors?in?Heart?Failure[J].Advances in Cardiovascular Diseases,2021,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.004]
[4]李少杰 苏康康 王震 谷剑 陈淑霞.钠-葡萄糖共转运蛋白2抑制剂对心律失常影响的研究进展[J].心血管病学进展,2023,(3):251.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.014]
LI S haojie,SU K angkang,WANG Z hen,et al.Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Arrhythmias[J].Advances in Cardiovascular Diseases,2023,(8):251.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.014]
[5]李胜男 谢亮 童嘉毅.阻塞性睡眠呼吸暂停的药物治疗研究进展[J].心血管病学进展,2023,(8):748.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.017]
LI Shengnan,XIE Liang,TONG Jiayi.Advancement of Drug Therapy in Obstructive Sleep Apnea Syndrome[J].Advances in Cardiovascular Diseases,2023,(8):748.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.017]
[6]林佳音 王莉莉 于小晴.胰高血糖素样肽-1受体激动剂对糖尿病心肌病的影响[J].心血管病学进展,2023,(11):1024.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.015]
LIN Jiayin,WANG Lili,YU Xiaoqing.Effect of Glucagon-Like Peptide-1 Receptor Agonist on Diabetes Cardiomyopathy[J].Advances in Cardiovascular Diseases,2023,(8):1024.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.015]
[7]高棣英 吴铿.SGLT2抑制剂对射血分数保留的心力衰竭的保护作用及机制研究进展[J].心血管病学进展,2024,(3):224.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.008]
GAO Diying,WU Keng.Protective Effect and Mechanism of SGLT2 Inhibitor on Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2024,(8):224.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.008]
[8]张严 宋可欣 姚朱华.钠-葡萄糖共转运蛋白2抑制剂对心肾综合征获益机制的研究进展[J].心血管病学进展,2024,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.002]
ZHANG Yan,SONG Kexin,YAO Zhuhua.Advances in the Beneficial Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor in Cardiorenal Syndrome[J].Advances in Cardiovascular Diseases,2024,(8):389.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.002]
[9]王一华 蒋玉娇 门冰欣 胡娜娜 张亚苹 张锦.铁死亡在射血分数保留的心力衰竭中的研究进展[J].心血管病学进展,2024,(9):816.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.011]
WANG Yihua,JIANG Yujiao,MEN Bingxin,et al.Ferroptosis in of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2024,(8):816.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.011]